Paper29439820
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES and 11 others. Eur Urol, 2018. Cited by 156 papers, by iCite.
Cite this record
ConductScience Library. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Papers, record 29439820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29439820
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
- PubMed
- Publication types
- Comparative Study, Journal Article, Observational Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics30
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Antagonists | Major topic |
| Androstenes | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Biomarkers, Tumor | Major topic |
| DNA Repair Enzymes | Major topic |
| Germ-Line Mutation | Major topic |
| Phenylthiohydantoin | Major topic |
| Prostatic Neoplasms, Castration-Resistant | Major topic |
| Aged | |
| Antigens, Neoplasm | |
| Ataxia Telangiectasia Mutated Proteins | |
| BRCA1 Protein | |
| BRCA2 Protein | |
| Benzamides | |
| Clinical Decision-Making | |
| DNA Mutational Analysis | |
| GPI-Linked Proteins | |
| Genetic Predisposition to Disease | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Proteins | |
| Nitriles | |
| Phenotype | |
| Precision Medicine | |
| Progression-Free Survival | |
| Prospective Studies | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA006973 | NCI NIH HHS | United States | P30CA006973 | PubMed and NIH | NIH RePORTER |
| P50 CA058236 | NCI NIH HHS | United States | P50CA058236 | PubMed and NIH | NIH RePORTER |
| R01 CA185297 | NCI NIH HHS | United States | R01CA185297 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 30360342 | Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide. | https://conductscience.org/library/papers/30360342 |
Source PubMed
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28259476 | Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. | Eur Urol | 2017 | https://conductscience.org/library/papers/28259476 | PubMed |
| 2 | 27433846 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27433846 | PubMed |
| 3 | 27989354 | Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. | Eur Urol | 2017 | https://conductscience.org/library/papers/27989354 | PubMed |
| 4 | 25454609 | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. | Eur Urol | 2015 | https://conductscience.org/library/papers/25454609 | PubMed |
| 5 | 18309951 | Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18309951 | PubMed |
| 6 | 28843286 | Integrative Clinical Genomics of Advanced Prostate Cancer. | Cell | 2015 | https://conductscience.org/library/papers/28843286 | PubMed |
| 7 | 24027196 | Androgen receptor signaling regulates DNA repair in prostate cancers. | Cancer Discov | 2013 | https://conductscience.org/library/papers/24027196 | PubMed |
| 8 | 26775620 | BRCAness revisited. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26775620 | PubMed |
| 9 | 28608931 | The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28608931 | PubMed |
| 10 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 11 | 26582918 | ClinVar: public archive of interpretations of clinically relevant variants. | Nucleic Acids Res | 2016 | https://conductscience.org/library/papers/26582918 | PubMed |
| 12 | 25255306 | Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. | Nat Commun | 2014 | https://conductscience.org/library/papers/25255306 | PubMed |
| 13 | 26746459 | Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. | JAMA | 2016 | https://conductscience.org/library/papers/26746459 | PubMed |
| 14 | 28573914 | Treatment strategies for DNA repair-deficient prostate cancer. | Expert Rev Clin Pharmacol | 2017 | https://conductscience.org/library/papers/28573914 | PubMed |
| 15 | 26510020 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26510020 | PubMed |
| 16 | 28314609 | Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer. | Eur Urol | 2017 | https://conductscience.org/library/papers/28314609 | PubMed |
| 17 | 24027197 | A hormone-DNA repair circuit governs the response to genotoxic insult. | Cancer Discov | 2013 | https://conductscience.org/library/papers/24027197 | PubMed |
Cited by98
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 156 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42832307 | Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology. | Oncologist | 2026 | https://conductscience.org/library/papers/42832307 | PubMed |
| 42754663 | CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer. | Oncogene | 2026 | https://conductscience.org/library/papers/42754663 | PubMed |
| 42667419 | Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer. | Hum Genet | 2026 | https://conductscience.org/library/papers/42667419 | PubMed |
| 42588618 | Real-World Outcomes of DNA Damage Repair Altered Metastatic Castration-Resistant Prostate Cancer: Insights from FFPE-Based Genomic Profiling. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588618 | PubMed |
| 42115448 | Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial. | World J Urol | 2026 | https://conductscience.org/library/papers/42115448 | PubMed |
| 42092965 | PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential. | J Transl Med | 2026 | https://conductscience.org/library/papers/42092965 | PubMed |
| 40971752 | Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40971752 | PubMed |
| 40891997 | Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. | BJU Int | 2025 | https://conductscience.org/library/papers/40891997 | PubMed |
| 40744833 | Prostate cancer germline variants with therapeutic implications. | Trends Mol Med | 2026 | https://conductscience.org/library/papers/40744833 | PubMed |
| 40736216 | Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/40736216 | PubMed |
| 40002869 | The Tight Relationship Between the Tumoral Microenvironment and Radium-223. | Biomedicines | 2025 | https://conductscience.org/library/papers/40002869 | PubMed |
| 40001885 | Early Detection of the Pathogenetic Variants of Homologous Recombination Repair Genes in Prostate Cancer: Critical Analysis and Experimental Design. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40001885 | PubMed |
| 39917165 | Interactions between key genes and pathways in prostate cancer progression and therapy resistance. | Front Oncol | 2025 | https://conductscience.org/library/papers/39917165 | PubMed |
| 39516637 | Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes. | BJC Rep | 2024 | https://conductscience.org/library/papers/39516637 | PubMed |
| 39455978 | Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39455978 | PubMed |
| 39450704 | Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39450704 | PubMed |
| 39333696 | Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). | Prostate Cancer Prostatic Dis | 2025 | https://conductscience.org/library/papers/39333696 | PubMed |
| 39301117 | Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency. | Urol Case Rep | 2024 | https://conductscience.org/library/papers/39301117 | PubMed |
| 39257456 | Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. | Clinicoecon Outcomes Res | 2024 | https://conductscience.org/library/papers/39257456 | PubMed |
| 38885246 | TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. | Oncologist | 2024 | https://conductscience.org/library/papers/38885246 | PubMed |
Genes54
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29439820
GET https://conductscience.org/api/papers/v1/29439820/cited_by?page=2